HealthAratus
IntelliStreamToolsFor VendorsHow It Works
Sign InGet Started
HEALTHARATUS BETA

See how HealthAratus builds intelligence →

Back
Company

Personalis

vendor1 tracked tool
imaging_diagnostics category intelligence

Tracked Tools by Personalis

P
PersonalisHealthAratus Score0.6

Personalis is an advanced genomics company specializing in precision oncology diagnostics, offering comprehensive tumor profiling (NeXT Dx) covering ~20,000 genes via full exome and transcriptome analysis, and ultra-sensitive minimal residual disease (MRD) detection (NeXT Personal) using circulating tumor DNA in blood samples. Clinical studies demonstrate detection of lung cancer recurrence 6-11 months ahead of imaging. Personalis partners with Tempus for co-commercialization and collaborates with NCI-designated cancer centers including UC San Diego Moores Cancer Center.

Company Intelligence

Tempus to acquire Personalis for $1.5B

3 months agodeployment

Tempus buys out cancer genomics partner Personalis in $1.5 billion deal

3 months agodeployment
HealthAratusHealthAratus

Intelligence for healthcare AI after deployment.

HealthAratus

  • How It Works
  • About

For Industry

  • For Users
  • For Vendors
  • For Hospitals & Healthcare Facilities
  • For AI Healthcare Investors

Company

  • Investor Relations
  • Beta Feedback & Support

Legal

  • Privacy Policy
  • Terms of Service
2026 — Powered by AI Health Labs Research

HealthAratus is the institutional standard for medical AI validation in the United States. The MOAT Protocol aggregates ground-truth performance signals from a credentialed network of 60,000 verified U.S. users, delivering real-world evidence that health systems, payers, and procurement leaders use to evaluate AI tools before deployment.

The HealthAratus Score is a composite reputation metric computed from four weighted factors: Evidence, Deployment, User Experience and Innovation. Scores are EWMA-smoothed daily and capped to prevent intra-day volatility.

Beta Feedback